News

Soligenix (NASDAQ: SNGX) Achieves Biological Efficacy in Phase 2a SGX945 Study for Behçet’s Disease
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing products for rare diseases, has completed its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in Behçet’s ...
PipelineReview.com11h
Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet’s Disease
The SGX945 proof of concept pilot study was an open-label study that enrolled 8 patients age 18 years or older with mild to ...